Submitted by Anonymous (not verified) on 19 September 2024 - 13:28
Opinion/decision on a Paediatric investigation plan (PIP): Beyfortus, Nirsevimab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Vaccines, PIP number: P/0296/2021
Source: